{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'deficit/hyperactivity disorder;', 'deficit/hyperactivity disorder;', 'CYP=cytochrome P450;', 'CYP=cytochrome P450;', 'IMP=investigational medicinal product;', 'IMP=investigational medicinal product;', 'SNRIs=serotonin-norepinephrine reuptake', 'SNRIs=serotonin-norepinephrine reuptake', 'inhibitor Note: No dosing changes can be', 'inhibitor Note: No dosing changes can be', 'made during the study.', 'made during the study.', 'Table 6:', 'Prohibited Antipsychotic Drugs', 'Table 6:', 'Prohibited Antipsychotic Drugs', 'Typical/first generation', 'Atypical/seco', 'Typical/first generation', 'Atypical/seco', 'antipsychotics', 'nd generation', 'antipsychotics', 'nd generation', 'antipsychotic', 'antipsychotic', 's', 'S', 'Chlorpromazine', 'Aripiprazole', 'Chlorpromazine', 'Aripiprazole', 'Haloperidol', 'Asenapine', 'Haloperidol', 'Asenapine', 'maleate', 'maleate', 'Loxapine', 'Clozapine', 'Loxapine', 'Clozapine', 'Molindone', 'Iloperidone', 'Molindone', 'Iloperidone', 'Perphenazine', 'Lurasidone', 'Perphenazine', 'Lurasidone', 'Pimozide', 'Olanzapine', 'Pimozide', 'Olanzapine', 'Prochlorperazine', 'Olanzapine/flu', 'Prochlorperazine', 'Olanzapine/flu', 'oxetine', 'oxetine', 'Thioridazine', 'Paliperidone', 'Thioridazine', 'Paliperidone', 'Thiothixene', 'Quetiapine', 'Thiothixene', 'Quetiapine', 'Trifluoperazine', 'Risperidone', 'Trifluoperazine', 'Risperidone', 'Promethazine-containing', 'Ziprasidone', 'Promethazine-containing', 'Ziprasidone', 'compounds', 'compounds', 'Fluphenazine', 'Tiapride', 'Fluphenazine', 'Tiapride', 'Note: This table does not apply in the', 'Note: This table does not apply in the', 'second week of washout for patients not', 'second week of washout for patients not', 'rolling over to the open-label extension', 'rolling over to the open-label extension', 'study (Study TV50717-CNS-30047).', 'study (Study TV50717-CNS-30047).', 'Table 8:', 'Other Prohibited Drugs', 'Table 8:', 'Other Prohibited Drugs', 'Generic', 'Class/clinical', 'Note', 'Generic', 'Class/clinical', 'Note', 'use', 'use', 'Cannabidio', 'Cannabis', 'Also', 'Cannabidio', 'Cannabis', 'Also', '1 oil', 'includes', '1 oil', 'includes', 'other forms', 'other forms', '193']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'of', 'of', 'cannabinoid', 'cannabinoid', 'S', 'S', 'Valbenazin', 'Vesicular', 'Ingrezza', 'Valbenazin', 'Vesicular', 'Ingrezza', 'e', 'monoamine', 'off-label', 'e', 'monoamine', 'off-label', 'transporter 2', 'transporter 2', 'inhibitor', 'inhibitor', 'Quinidine', 'Class I', 'Strong', 'Quinidine', 'Class I', 'Strong', 'antiarrhythmic', 'CYP2D6', 'antiarrhythmic', 'CYP2D6', 'agent', 'inhibitor', 'agent', 'inhibitor', 'Terbinafine', 'Antifungal', 'Weak', 'Terbinafine', 'Antifungal', 'Weak', 'medication', 'CYP2D6', 'medication', 'CYP2D6', 'inhibitor', 'inhibitor', '194']\n\n###\n\n", "completion": "END"}